---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-010947"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-01-19T23:59:59+00:00"
generated_at: "2026-06-20T13:12:56.866388+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies CMO Suyash Prasad departs effective immediately

## Summary
- Chief Medical Officer Suyash Prasad separated from Taysha on Jan 12, 2023 by mutual agreement.
- Separation agreement terms not yet finalized; company to file further details later.
- No replacement named; CFO signed the 8-K filing.

## SEC filing metadata
- accession: 0001193125-23-010947
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-01-19T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523010947/0001193125-23-010947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523010947/d425122d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-010947
- JSON: https://secwatch.observer/filing/0001193125-23-010947.json
- Plain text: https://secwatch.observer/filing/0001193125-23-010947.txt

## Key facts
- Executive change
  Suyash Prasad departed as Chief Medical Officer at Taysha Gene Therapies, Inc..
  - Action: separated
  - Role: Chief Medical Officer
  source text: On January 12, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) and Suyash Prasad, the Company’s Chief Medical Officer, mutually agreed to Dr. Prasad’s separation from the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523010947/0001193125-23-010947-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.